Quince Therapeutics (QNCX) Free Cash Flow (2018 - 2026)

Quince Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$7.6 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 21.77% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$39.7 million (down 18.31% YoY), while the FY2025 annual figure was -$41.8 million, down 29.9% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$7.6 million, up from -$10.5 million in the prior quarter.
• The five-year high for Free Cash Flow was -$3.7 million in Q1 2023, with the low at -$16.1 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$7.7 million (2024), against an average of -$8.5 million.
• The sharpest annual moves came in 2023 and 2024: Free Cash Flow surged 76.98% in 2023, then tumbled 129.37% in 2024.
• Quince Therapeutics' Free Cash Flow stood at -$5.9 million in 2022, then declined by 3.2% to -$6.1 million in 2023, then declined by 25.94% to -$7.7 million in 2024, then slumped by 36.43% to -$10.5 million in 2025, then climbed by 27.26% to -$7.6 million in 2026.
• Business Quant data shows QNCX's Free Cash Flow at -$7.6 million in Q1 2026, -$10.5 million in Q4 2025, and -$10.0 million in Q3 2025.